Local lung cancer drug approved - (Shanghai Daily via NewsPoints Desk)

  • Jiangsu-based Hansoh Pharmaceutical said it received marketing approval for the first domestic therapy for patients with non-small-cell lung cancer with certain types of gene mutation, reported Shanghai Daily.

  • The news source said almonertinib mesilate is a third-generation EGFR tyrosine kinase inhibitor for patients who are T790M-mutation-positive.

  • According to the news source, the drug is the first of its kind which is locally developed to be approved by China's National Medical Products Administration.

To read more NewsPoints articles, click here.

Reference Articles